Clinical Trials
9 trialsNCT01846390 2026-03-27
Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma
Canadian Cancer Trials Group
Phase 1 Completed
NCT01998035 2024-08-22
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
Columbia University
Phase 1/2 Terminated
NCT01947140 2022-11-23
PDX+Romi
Columbia University
Phase 1/2 Completed
NCT02181218 2020-11-17
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas
Washington University School of Medicine
Phase 1 Completed
NCT01897012 2019-01-28
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
National Cancer Institute (NCI)
Phase 1 Completed
NCT02281279 2016-08-11
Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
Mayo Clinic
Phase 1/2 Withdrawn
NCT00383565 2014-05-20
FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00077194 2013-02-11
FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00042822 2011-05-17
FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed